PTTG1
Basic information
Region (hg38): 5:160421855-160428739
Previous symbols: [ "TUTR1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PTTG1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 10 | 10 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 10 | 0 | 1 |
Variants in PTTG1
This is a list of pathogenic ClinVar variants found in the PTTG1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-160422317-C-T | not specified | Uncertain significance (Nov 30, 2021) | ||
5-160422371-C-T | not specified | Uncertain significance (Sep 17, 2021) | ||
5-160422376-G-A | not specified | Uncertain significance (May 12, 2024) | ||
5-160422380-G-T | not specified | Uncertain significance (Aug 11, 2024) | ||
5-160422713-C-G | not specified | Uncertain significance (Jan 04, 2024) | ||
5-160422714-A-G | not specified | Uncertain significance (Oct 16, 2024) | ||
5-160422750-C-T | not specified | Uncertain significance (Oct 07, 2024) | ||
5-160424256-A-C | not specified | Uncertain significance (Aug 19, 2024) | ||
5-160424311-C-A | not specified | Uncertain significance (Dec 28, 2023) | ||
5-160424322-A-G | not specified | Uncertain significance (Aug 02, 2023) | ||
5-160427719-T-A | not specified | Uncertain significance (Sep 26, 2023) | ||
5-160427754-C-T | not specified | Uncertain significance (Jul 17, 2024) | ||
5-160427763-C-G | not specified | Uncertain significance (Mar 19, 2024) | ||
5-160427783-A-G | not specified | Uncertain significance (Jan 24, 2024) | ||
5-160427815-G-T | not specified | Uncertain significance (Apr 11, 2023) | ||
5-160427824-G-C | not specified | Likely benign (Mar 25, 2024) | ||
5-160428609-G-T | not specified | Uncertain significance (Sep 24, 2024) | ||
5-160428632-C-T | not specified | Uncertain significance (Mar 06, 2023) | ||
5-160428637-C-T | Benign (Jul 23, 2018) | |||
5-160428674-A-C | not specified | Uncertain significance (Jun 29, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PTTG1 | protein_coding | protein_coding | ENST00000393964 | 5 | 6920 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.000422 | 0.662 | 125733 | 0 | 15 | 125748 | 0.0000596 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.961 | 78 | 106 | 0.737 | 0.00000503 | 1300 |
Missense in Polyphen | 11 | 27.791 | 0.39582 | 387 | ||
Synonymous | -0.0264 | 41 | 40.8 | 1.01 | 0.00000214 | 409 |
Loss of Function | 0.748 | 6 | 8.33 | 0.720 | 3.48e-7 | 118 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000152 | 0.000152 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.0000440 | 0.0000439 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000131 | 0.000131 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Regulatory protein, which plays a central role in chromosome stability, in the p53/TP53 pathway, and DNA repair. Probably acts by blocking the action of key proteins. During the mitosis, it blocks Separase/ESPL1 function, preventing the proteolysis of the cohesin complex and the subsequent segregation of the chromosomes. At the onset of anaphase, it is ubiquitinated, conducting to its destruction and to the liberation of ESPL1. Its function is however not limited to a blocking activity, since it is required to activate ESPL1. Negatively regulates the transcriptional activity and related apoptosis activity of TP53. The negative regulation of TP53 may explain the strong transforming capability of the protein when it is overexpressed. May also play a role in DNA repair via its interaction with Ku, possibly by connecting DNA damage-response pathways with sister chromatid separation. {ECO:0000269|PubMed:10411507, ECO:0000269|PubMed:11238996, ECO:0000269|PubMed:11371342, ECO:0000269|PubMed:12355087}.;
- Pathway
- Cell cycle - Homo sapiens (human);Oocyte meiosis - Homo sapiens (human);HTLV-I infection - Homo sapiens (human);Cell Cycle;Regulation of sister chromatid separation at the metaphase-anaphase transition;Separation of Sister Chromatids;Mitotic Anaphase;Mitotic Metaphase and Anaphase;M Phase;APC/C:Cdc20 mediated degradation of Securin;APC/C:Cdc20 mediated degradation of mitotic proteins;Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins;APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1;APC/C-mediated degradation of cell cycle proteins;Regulation of mitotic cell cycle;Cell Cycle;Cell Cycle, Mitotic
(Consensus)
Recessive Scores
- pRec
- 0.317
Intolerance Scores
- loftool
- 0.533
- rvis_EVS
- -0.14
- rvis_percentile_EVS
- 42.88
Haploinsufficiency Scores
- pHI
- hipred
- Y
- hipred_score
- 0.707
- ghis
- 0.703
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.968
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Low | Low | Low |
Primary Immunodeficiency | Low | Low | Low |
Cancer | Low | Low | Low |
Mouse Genome Informatics
- Gene name
- Pttg1
- Phenotype
- homeostasis/metabolism phenotype; cellular phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); endocrine/exocrine gland phenotype; growth/size/body region phenotype; embryo phenotype; renal/urinary system phenotype; immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- DNA repair;regulation of transcription by RNA polymerase II;transcription by RNA polymerase II;spermatogenesis;negative regulation of endopeptidase activity;anaphase-promoting complex-dependent catabolic process;homologous chromosome segregation;chromosome organization;cell division;negative regulation of mitotic sister chromatid separation
- Cellular component
- nucleus;cytoplasm;cytosol
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;cysteine-type endopeptidase inhibitor activity;protein binding;SH3 domain binding